Webinar Today

7,132 upcoming
Medical

Topics › Medical & Clinical

ICH S13 Draft Guideline: The Well-Characterized ONT and Opportunities for Tailored Nonclinical Development

Free

Length
1 hr
Topic
Medical & Clinical

Get notified when the recording is available

We’ll email you once, when this recording is ready, with an unsubscribe link. See our privacy policy.

About this webinar

Hosted by the SOT Biotechnology Specialty Section, Drug Discovery Toxicology Specialty Section, and Regulatory and Safety Evaluation Specialty Section

The draft ICH S13 guidance, Nonclinical Safety Evaluation of Oligonucleotide-Based Therapeutics, introduces a harmonized framework for the nonclinical development of ONTs. This webinar will provide a high-level overview of the guidance, with emphasis on the well-characterized ONT concept and opportunities to leverage prior knowledge to support more focused, efficient, and scientifically justified nonclinical programs. Additional discussion will highlight risk-based, WoE approaches, new approach methodologies, and other ONT-specific considerations that may enable more tailored development strategies. A panel of ICH S13 Expert Working Group members will discuss the draft guidance and address questions during a panel discussion and Q&A.

Speakers

Tod Harper, PhD, DABT, Scientific Director, Amgen

Xuan Chi, PhD, Supervisory Pharmacologist, US FDA

Jen Sisler, PhD, DABT, Director of Toxicology, Eli Lily

More Medical webinars 862

All Medical →

All Medical (862)